Oncolytic adenovirus encoding AEG1/CD3 bispecific T-cell engager potentiates antitumor immunity against lung cancer

Lung cancer remains one of the most formidable challenges in modern medicine, particularly a type called non-small cell lung cancer, which accounts for the vast majority of cases. While treatments like surgery, radiation, and chemotherapy have long been the standard, they often struggle against tumors that develop resistance or hide within an environment that suppresses the body's natural defenses. In recent years, immunotherapy has emerged as a powerful new strategy, aiming to wake up the patient's own immune system to recognize and destroy cancer cells. However, even these advanced treatments do not work for everyone, and the tumors can sometimes remain shielded from the immune attack. A key obstacle is that many cancer cells produce specific proteins that help them grow and spread, while simultaneously making the tumor a hostile place for immune cells to enter. One such protein, known as AEG-1, is found in high levels in many lung cancers and is linked to poor outcomes for patients. It acts as a driver for the disease, helping the cancer multiply and resist treatment.

Scientists have also developed a type of drug called a bispecific T-cell engager, which acts like a bridge. One end of this drug grabs onto a cancer cell, and the other end grabs onto a T cell, a soldier of the immune system. By physically linking the two, the drug forces the T cell to attack the cancer. Yet, when these drugs are injected into the bloodstream, they often break down too quickly to be effective, and they struggle to penetrate deep into solid tumors. To solve these problems, researchers are exploring the use of oncolytic adenoviruses, which are modified viruses that naturally seek out and infect cancer cells. Once inside, these viruses replicate and burst the cancer cells open, a process called lysis. The idea is to combine these two approaches: use the virus not just to kill the cancer directly, but also as a factory inside the tumor to produce the bridge-building drugs right where they are needed.

A team of researchers at Xi'an International Medical Center Hospital has taken this concept and applied it to lung cancer by creating a new, engineered virus. They designed a recombinant oncolytic adenovirus, which they named OAd-AEG1-BiTE, to carry the instructions for making a specific bridge-building drug. This drug is designed to target the AEG-1 protein found on lung cancer cells and link them to CD3, a marker found on T cells. The researchers wanted to see if this virus could infect lung cancer cells, produce the bridge drug, and then recruit the immune system to destroy the tumor more effectively than either the virus or the drug could do alone.

To test this, the team first built the virus in the laboratory. They constructed a genetic sequence that would produce the bridge protein, linking a part that recognizes AEG-1 with a part that recognizes CD3. They inserted this sequence into a harmless adenovirus backbone that had been stripped of its ability to cause disease in healthy cells but kept its ability to infect and kill cancer cells. They also created a control virus that looked the same but carried a harmless green fluorescent protein instead of the bridge instructions. After growing these viruses in human cells, they confirmed that the new virus could successfully enter lung cancer cells and begin producing the bridge protein. Tests showed that the cells infected with the new virus were making high levels of the bridge protein's genetic message and the protein itself, while the control cells did not.

The researchers then moved to test how well this system worked in a dish. They took human lung cancer cells and mixed them with human immune cells taken from healthy donors. They added the new virus to some of these mixtures and the control virus to others. Using a system that monitors cell health in real time, they observed what happened when the immune cells were introduced. The results were striking. In the groups where the new virus was present, the immune cells were far more effective at killing the cancer cells. The cancer cells died off much faster and in greater numbers compared to the groups with the control virus or no virus at all. This effect was dependent on the number of immune cells present; when more immune cells were added, the killing power increased significantly. The team also measured the chemicals released by the immune cells during this process. They found that the groups treated with the new virus released much higher levels of substances known to activate and direct immune attacks, such as interleukin-2, interferon-gamma, and tumor necrosis factor-alpha. These chemicals are signals that the immune system is engaged and working hard. In contrast, the levels of another chemical, GM-CSF, did not change significantly, suggesting the response was highly specific to the T cells.

To see if this approach worked in a living system, the researchers turned to a model using mice. They injected human lung cancer cells under the skin of mice to create small tumors. Once the tumors were established, they divided the mice into groups. One group received an injection of the new virus directly into the tumor, followed by an injection of human immune cells into their bloodstream. Another group received the control virus and immune cells, while a third group received a saltwater solution. Over the course of the study, the researchers measured the size of the tumors and the weight of the mice. The mice treated with the new virus showed a clear reduction in tumor growth. Their tumors remained significantly smaller than those in the control groups, which continued to grow at a steady pace. Importantly, the mice did not lose weight or show signs of illness, indicating that the treatment was not toxic to the animals. When the researchers examined the tumors at the end of the study, they found that the genetic instructions for the bridge protein were still present and active in the tumors of the treated mice, confirming that the virus had successfully delivered its cargo and kept producing the drug inside the tumor.

The study suggests that this combined approach offers a promising way to overcome the limitations of current immunotherapies. By using the virus to deliver the bridge-building drug directly into the tumor, the treatment achieves a high concentration of the drug right where it is needed, avoiding the rapid breakdown that happens when the drug is given through the bloodstream. This method effectively turns the tumor into a site of intense immune activity, recruiting the body's own defenses to attack the cancer from the inside out. While the researchers noted that their study was limited to a single type of lung cancer cell line and a specific mouse model, the results provide a strong foundation for further investigation. The work demonstrates that engineering a virus to produce a targeted immune bridge can significantly enhance the ability of the immune system to fight lung cancer, offering a new path forward for developing more effective treatments for patients who currently have few options.